Literature DB >> 25455693

Dyskinesias and motor symptoms onset in Parkinson disease.

Anna Latorre1, Maria Carmela Bloise1, Carlo Colosimo1, Francesca Di Biasio2, Giovanni Defazio3, Alfredo Berardelli4, Giovanni Fabbrini5.   

Abstract

PURPOSE: To assess, using a longitudinal follow-up study design, the relationship between the body site of motor symptoms onset and that of dyskinesias (LID) onset in 70 PD patients in whom LID were absent at the baseline but appeared at one of the follow-up visits; to investigate the demographic and clinical features associated with different sites of LID onset.
METHODS: Motor symptoms onset was retrospectively determined by asking patients which body part had first been affected by motor impairment. The site of LID onset was determined objectively in one of the follow-up visits.
RESULTS: Motor symptoms started in the limbs in all patients (unilaterally in 91.4% and bilaterally in 8.6% of the patients). LID started unilaterally in the limbs in 25.8%, bilaterally in the limbs in 7.1%, in the cranio-cervical-axial region in 40% and in both the cranio-cervical-axial region and limbs in 27.1% of the patients. No significant association emerged between the site of motor symptoms onset and that of LID onset; a correlation did emerge between the site of motor symptoms onset and that of LID onset in patients with unilateral onset of both motor symptoms and LID. No differences were detected when the subgroups of patients with LID onset in different body regions were compared.
CONCLUSIONS: The partial association between the body site of motor symptoms and of LID onset likely reflects pathophysiological mechanisms underlying LID.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dyskinesias; Levodopa; Parkinson disease

Mesh:

Substances:

Year:  2014        PMID: 25455693     DOI: 10.1016/j.parkreldis.2014.10.002

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  4 in total

1.  The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias.

Authors:  Vishakh Iyer; Kala Venkiteswaran; Sandip Savaliya; Christopher A Lieu; Erin Handly; Timothy P Gilmour; Allen R Kunselman; Thyagarajan Subramanian
Journal:  Neurobiol Dis       Date:  2021-08-27       Impact factor: 5.996

2.  Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease.

Authors:  Rodolphe Hajj; Aude Milet; Damien Toulorge; Nathalie Cholet; Julien Laffaire; Julie Foucquier; Sandra Robelet; Richard Mitry; Mickael Guedj; Serguei Nabirotchkin; Ilya Chumakov; Daniel Cohen
Journal:  Sci Rep       Date:  2015-11-06       Impact factor: 4.379

3.  Hyperbaric oxygen treatment for Parkinson's disease with severe depression and anxiety: A case report.

Authors:  Jin-Jin Xu; Si-Tong Yang; Ying Sha; Yuan-Yuan Ge; Jian-Meng Wang
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

4.  A Retrospective Imaging Evaluation of Presynaptic Dopaminergic Degeneration in Multiple System Atrophy with Levodopa Induced Dyskinesia.

Authors:  Shin-Ichi Ueno; Genko Oyama; Kazuaki Kanai; Taku Hatano; Yasushi Shimo; Nobutaka Hattori
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2020-06-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.